A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study.

Front Oncol · 2021 · PMC8484871 · PMID 34604072

Europe PMC DOI

hedged sentences

0.1551

closest p · 3.1× alpha

0.1551

boldest claim

The sentences

a numerical trendp = 0.1551not close (p > 0.1)

There was a numerical trend toward superior 1-year RFS among patients with PD-L1 positive disease compared to those with PD-L1 negative disease, using CPS of ≥10 (100% vs . 66.7%, p = 0.1551) and ≥1 (84.2% vs . 61.1%, p = 0.1510) cutoffs.

also in 1,012 other papers

showed a trendno p-value reported

Our study showed a trend toward improved RFS and OS in patients with PD-L1 positive disease.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.